Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    09-December-2000      
Issue 240 Next Update - 14:00 UTC 08:00 EST    10-December-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 09-December-2000:

The following stories appear in full on today's Vidyya Medical News Service Web site.

The Food and Drug Administration (FDA) today approved a new treatment for atopic dermatitis (eczema) - a non-contagious skin condition that can cause redness, itching and oozing lesions. The drug is Protopic (tacrolimus) Ointment (0.1% and 0.03% for adults and 0.03% for children 2 years and older). The drug is for patients with moderate to severe eczema, for whom standard eczema therapies are deemed inadvisable because of potential risks, or who are not adequately treated by or who are intolerant of standard eczema therapies.

For more information: FDA Approves New Treatment For Eczema

Foods that were contaminated in Michigan in 1973, when a fire retardant containing the chemical polybrominated biphenyl PBB was accidentally mixed with animal feed, have been associated with an early onset of menstruation and pubic hair in some daughters of the women exposed, scientists reported in the journal Epidemiology (Nov. 2000, Vol. 11, No. 6.). The daughters of the most highly exposed women began menstruation, on average, before they reached their twelfth birthdays.

For more information: PBBs In Fire Retardant Associated With Early Menstruation

Vitamin C, beta-carotene, and an anti-bacterial treatment may -- singly or in combination -- help prevent stomach cancer, according to a long-term clinical trial involving more than 600 people at high risk of developing the disease. The results of the trial appear in the Dec. 6, 2000, issue of the Journal of the National Cancer Institute.

For more information: Vitamins, Anti-Bacterials May Prevent Stomach Cancer

A widely available standard test that detects bleeding in the stomach or bowel (gastrointestinal tract) may help prevent the development of colon cancer. The results, published in the 30 November 2000, issue of the New England Journal of Medicine, showed that persons who underwent a FOBT (fecal occult-blood test) and received further evaluation were less likely to develop colon cancer than people who did not undergo the test. The FOBT looks for occult or hidden blood in the stool (feces), which usually indicates bleeding in the gastrointestinal tract.

For more information: Test For Blood In Stool May Help Prevent Colon Cancer

The drug STI-571 will soon enter clinical trials for glioblastoma, a kind of brain tumor, and for gastrointestinal stromal tumors and leukemia under a new agreement between the National Cancer Institute and Novartis Pharmaceuticals, the company that makes STI-571. Initially tested in chronic myelogenous leukemia, the experimental drug has also shown promise for some solid tumors.

For more information: Trials Will Test STI-571 In More Cancers

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Vidyya Home |  Home Of Our Sponsor, Vidyya. | Vidyya Archives | Search Vidyya  | Visit Our Library | Subscribe To Our News Service | All About Us | Get Vidyya For Your Website
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.